Strategic asset sale Attralus recently divested assets to Bayer, indicating flexibility in monetization and potential for partnership-driven exits or co-development opportunities in imaging and diagnostic modalities.

Finite funding runway With a total funding of 197 million and a recent 56 million financing, there is appetite for scalable collaborations, licensing, or milestone-rich deals to accelerate clinical programs while de-risking capital burn.

Orphan drug position AT-01 and related PAR therapies carry orphan drug relevance; potential sales opportunities include partnerships with large pharma for accelerated orphan indications and reimbursement pathways in niche amyloidosis markets.

Clinical stage traction Active preclinical and clinical data generation in amyloidosis and CAR-M approaches suggests opportunities for research collaborations, co-development, and access to translational biomarkers for companion diagnostics.

Global outreach potential Participation in international conferences and collaborations with academic centers (e.g., Brigham and Women's Hospital, University of Tennessee) create openings for strategic academic partnerships, consultant networks, and joint grant-funded programs to expand trial sites.